Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 32

1.

Safety and Immunogenicity of a Tetravalent Dengue DNA Vaccine Administered with a Cationic Lipid-Based Adjuvant in a Phase 1 Clinical Trial.

Danko JR, Kochel T, Teneza-Mora N, Luke TC, Raviprakash K, Sun P, Simmons M, Moon JE, De La Barrera R, Martinez LJ, Thomas SJ, Kenney RT, Smith L, Porter KR.

Am J Trop Med Hyg. 2018 Mar;98(3):849-856. doi: 10.4269/ajtmh.17-0416. Epub 2018 Jan 18.

2.

A cytomegalovirus DNA vaccine induces antibodies that block viral entry into fibroblasts and epithelial cells.

McVoy MA, Lee R, Saccoccio FM, Hartikka J, Smith LR, Mahajan R, Wang JB, Cui X, Adler SP.

Vaccine. 2015 Dec 16;33(51):7328-7336. doi: 10.1016/j.vaccine.2015.10.078. Epub 2015 Oct 24.

3.

Fusion of antigen to a dendritic cell targeting chemokine combined with adjuvant yields a malaria DNA vaccine with enhanced protective capabilities.

Luo K, Zhang H, Zavala F, Biragyn A, Espinosa DA, Markham RB.

PLoS One. 2014 Mar 5;9(3):e90413. doi: 10.1371/journal.pone.0090413. eCollection 2014.

4.

Preclinical evaluation of Vaxfectin-adjuvanted Vero cell-derived seasonal split and pandemic whole virus influenza vaccines.

Smith LR, Wodal W, Crowe BA, Kerschbaum A, Bruehl P, Schwendinger MG, Savidis-Dacho H, Sullivan SM, Shlapobersky M, Hartikka J, Rolland A, Barrett PN, Kistner O.

Hum Vaccin Immunother. 2013 Jun;9(6):1333-45. doi: 10.4161/hv.24209. Epub 2013 Mar 6.

5.

Vaccination with Vaxfectin(®) adjuvanted SIV DNA induces long-lasting humoral immune responses able to reduce SIVmac251 Viremia.

Kulkarni V, Rosati M, Valentin A, Jalah R, Alicea C, Yu L, Guan Y, Shen X, Tomaras GD, LaBranche C, Montefiori DC, Irene C, Prattipati R, Pinter A, Sullivan SM, Pavlakis GN, Felber BK.

Hum Vaccin Immunother. 2013 Oct;9(10):2069-80. doi: 10.4161/hv.25442. Epub 2013 Jul 2.

6.

Vaxfectin adjuvant improves antibody responses of juvenile rhesus macaques to a DNA vaccine encoding the measles virus hemagglutinin and fusion proteins.

Lin WH, Vilalta A, Adams RJ, Rolland A, Sullivan SM, Griffin DE.

J Virol. 2013 Jun;87(12):6560-8. doi: 10.1128/JVI.00635-13. Epub 2013 Apr 3.

7.

A Vaxfectin(®)-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes.

Veselenak RL, Shlapobersky M, Pyles RB, Wei Q, Sullivan SM, Bourne N.

Vaccine. 2012 Nov 19;30(49):7046-51. doi: 10.1016/j.vaccine.2012.09.057. Epub 2012 Oct 4.

8.

A dengue DNA vaccine formulated with Vaxfectin® is well tolerated, and elicits strong neutralizing antibody responses to all four dengue serotypes in New Zealand white rabbits.

Raviprakash K, Luke T, Doukas J, Danko J, Porter K, Burgess T, Kochel T.

Hum Vaccin Immunother. 2012 Dec 1;8(12):1764-8. doi: 10.4161/hv.21806. Epub 2012 Oct 2.

9.

Preclinical evaluation of the immunogenicity and safety of plasmid DNA-based prophylactic vaccines for human cytomegalovirus.

Hartikka J, Bozoukova V, Morrow J, Rusalov D, Shlapobersky M, Wei Q, Boutsaboualoy S, Ye M, Wloch MK, Doukas J, Sullivan S, Rolland A, Smith LR.

Hum Vaccin Immunother. 2012 Nov 1;8(11):1595-606. doi: 10.4161/hv.21225. Epub 2012 Aug 24.

10.

Vaxfectin-adjuvanted plasmid DNA vaccine improves protection and immunogenicity in a murine model of genital herpes infection.

Shlapobersky M, Marshak JO, Dong L, Huang ML, Wei Q, Chu A, Rolland A, Sullivan S, Koelle DM.

J Gen Virol. 2012 Jun;93(Pt 6):1305-15. doi: 10.1099/vir.0.040055-0. Epub 2012 Mar 7.

11.

Immunogenicity and protective efficacy of a vaxfectin-adjuvanted tetravalent dengue DNA vaccine.

Porter KR, Ewing D, Chen L, Wu SJ, Hayes CG, Ferrari M, Teneza-Mora N, Raviprakash K.

Vaccine. 2012 Jan 5;30(2):336-41. doi: 10.1016/j.vaccine.2011.10.085. Epub 2011 Nov 12.

PMID:
22085548
12.

Nonclinical biodistribution, integration, and toxicology evaluations of an H5N1 pandemic influenza plasmid DNA vaccine formulated with Vaxfectin®.

Doukas J, Morrow J, Bellinger D, Hilgert T, Martin T, Jones D, Mahajan R, Rusalov D, Sullivan S, Rolland A.

Vaccine. 2011 Jul 26;29(33):5443-52. doi: 10.1016/j.vaccine.2011.05.060. Epub 2011 Jun 17.

PMID:
21641955
13.

Vaxfectin: a versatile adjuvant for plasmid DNA- and protein-based vaccines.

Sullivan SM, Doukas J, Hartikka J, Smith L, Rolland A.

Expert Opin Drug Deliv. 2010 Dec;7(12):1433-46. doi: 10.1517/17425247.2010.538047. Review.

PMID:
21118032
14.

Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin.

Smith LR, Wloch MK, Ye M, Reyes LR, Boutsaboualoy S, Dunne CE, Chaplin JA, Rusalov D, Rolland AP, Fisher CL, Al-Ibrahim MS, Kabongo ML, Steigbigel R, Belshe RB, Kitt ER, Chu AH, Moss RB.

Vaccine. 2010 Mar 16;28(13):2565-72. doi: 10.1016/j.vaccine.2010.01.029. Epub 2010 Jan 29.

PMID:
20117262
15.

Vaxfectin enhances both antibody and in vitro T cell responses to each component of a 5-gene Plasmodium falciparum plasmid DNA vaccine mixture administered at low doses.

Sedegah M, Rogers WO, Belmonte M, Belmonte A, Banania G, Patterson NB, Rusalov D, Ferrari M, Richie TL, Doolan DL.

Vaccine. 2010 Apr 9;28(17):3055-65. doi: 10.1016/j.vaccine.2009.10.044. Epub 2009 Oct 30.

PMID:
19879998
16.

Analysis of biomarkers after intramuscular injection of Vaxfectin-formulated hCMV gB plasmid DNA.

Vilalta A, Shlapobersky M, Wei Q, Planchon R, Rolland A, Sullivan S.

Vaccine. 2009 Dec 9;27(52):7409-17. doi: 10.1016/j.vaccine.2009.08.075. Epub 2009 Sep 5.

PMID:
19735757
17.

Vaxfectin-adjuvanted seasonal influenza protein vaccine: correlation of systemic and local immunological markers with formulation parameters.

Shlapobersky M, Wei Q, Sullivan S, Vilalta A.

Vaccine. 2009 Oct 30;27(46):6404-10. doi: 10.1016/j.vaccine.2009.06.087. Epub 2009 Jul 14.

PMID:
19607952
18.

Vaxfectin, a cationic lipid-based adjuvant for protein-based influenza vaccines.

Hartikka J, Bozoukova V, Yang CK, Ye M, Rusalov D, Shlapobersky M, Vilalta A, Wei Q, Rolland A, Smith LR.

Vaccine. 2009 Oct 30;27(46):6399-403. doi: 10.1016/j.vaccine.2009.06.014. Epub 2009 Jun 21.

PMID:
19552895
19.

Use of Vaxfectin adjuvant with DNA vaccine encoding the measles virus hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques against measles virus.

Pan CH, Jimenez GS, Nair N, Wei Q, Adams RJ, Polack FP, Rolland A, Vilalta A, Griffin DE.

Clin Vaccine Immunol. 2008 Aug;15(8):1214-21. doi: 10.1128/CVI.00120-08. Epub 2008 Jun 4.

20.

Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus.

Lalor PA, Webby RJ, Morrow J, Rusalov D, Kaslow DC, Rolland A, Smith LR.

J Infect Dis. 2008 Jun 15;197(12):1643-52. doi: 10.1086/588431.

PMID:
18513153

Supplemental Content

Loading ...
Support Center